Drug Discovery Featured Articles & Applications
-
2024 LIMS Trends
3/15/2024
The laboratory information management system (LIMS) landscape in 2024 is a dynamic one, driven by accelerating advancements in technology and evolving industry needs. This article shares the four key trends.
-
Drugging The Undruggable: Strategies And Future Directions
3/7/2024
Progress with PROTACs and molecular glues hasn’t come without challenges, particularly in identifying the right chemistry starting point for drug development — a process known as hit discovery. This article looks at the role of CRISPR, screening assays, and more.
-
8 Key Takeaways Of The Proposed FDA Modernization Act 3.0
3/6/2024
On Feb. 6, 2024, new legislation was introduced in the House of Representatives: the FDA Modernization Act 3.0. It aims to reduce and replace the use of animals in nonclinical research, improve predictivity of nonclinical testing, and potentially reduce drug development times. This article shares an overview. Note that the proposed legislation would still need to go through its course of passing the House and Senate and being signed by the president before becoming a law.
-
FDA's Updated Guidance On Human Genome Editing: New Implications & Remaining Questions
2/27/2024
On Jan. 29, 2024, the FDA released the final version of the guidance document on human gene therapy products incorporating genome editing. This article shares what changed between the draft and now final version of the guidance, and what open questions remain for the industry and scientific community to help resolve.
-
AI's Role In Advancing Rare Disease Research
2/27/2024
IndoUSrare experts explore the global issues in rare disease research and examine how AI is poised to revolutionize the diagnosis and treatment of these often-overlooked conditions.
-
FDA's CBER Issues Final Guidance For CAR T Cell Products
2/15/2024
The FDA issued the final guidance document, Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products, on January 29. This article shares a useful and thorough summary of the guidance and where it differs (or not) from the earlier draft version of the guidance.
-
PROTACs And Molecular Glues: Rethinking What Is Possible
2/9/2024
This article explores the potential of novel small molecule approaches to address undruggable targets in oncology, including PROteolysis TArgeting Chimeras (PROTACs) and molecular glues, and how they work.
-
2024 And Beyond: The State Of Alzheimer's Disease Research And Drug Development
2/7/2024
The ongoing advancements in both drug delivery and therapeutic strategies underscore a growing wealth of progress in the battle against Alzheimer's disease.
-
Indo-U.S. Collaboration Can Accelerate Drug Discovery — Here's How
1/30/2024
Innovation in drug discovery can suppress development costs, ultimately improving patient access. Collaborations between India and the U.S. promise to accelerate that innovation on several fronts.
-
FDA Draft Guidance On “Rare Diseases: Considerations For The Development Of Drugs And Biological Products”
1/26/2024
Accenture Applied Life Science Solutions' Raj Bandaru, Ph.D. breaks down, summarizes, and shares detailed insight on the recent FDA Draft Guidance that addresses “Rare Diseases: Considerations for the Development of Drugs and Biological Products.”